{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:57:15Z","timestamp":1785412635774,"version":"3.56.0"},"reference-count":72,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005888","name":"Medical University of Lodz","doi-asserted-by":"crossref","award":["503\/3-011-01\/503-31-001"],"award-info":[{"award-number":["503\/3-011-01\/503-31-001"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"crossref"}]},{"award":["503\/3-011-01\/503-31-001"],"award-info":[{"award-number":["503\/3-011-01\/503-31-001"]}],"id":[{"id":"https:\/\/ror.org\/02t4ekc95","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Alcohol use disorder (AUD) remains a crucial public health challenge worldwide. The currently available medications for AUD remain limited in the number and efficacy, meaning that the development of new treatments is of critical importance. Agonists of glucagon\u2013like peptide\u20131 receptor (GLP\u20131RAs) have recently received attention as a potential anti\u2013addiction treatment, particularly in AUD. This review presents data from preclinical studies in rodents and non\u2013human primates, registered clinical trials, observational studies, and social media posts, investigating the effects of GLP\u20131RAs on alcohol\u2013related behaviors and consumption. Several GLP1\u2013RAs and tirzepatide (a dual agonist of GLP\u20131R and glucose\u2013dependent insulinotropic polypeptide receptor; GIP\u2013R) reduced alcohol consumption and alcohol\u2013seeking behaviors, alcohol\u2013induced locomotor stimulation and memory of alcohol reward, and suppressed relapse drinking in rodents. In addition, they prevent acute alcohol from activating the mesolimbic dopamine system. There are limited human data on the role of the GLP\u20131 system in AUD. In registered clinical trials, exenatide, semaglutide, and dulaglutide reduced alcohol consumption. Pharmacoepidemiologic studies documented a decreased risk of alcohol\u2013related events in AUD patients using various GLP\u20131RAs and tirzepatide. Together, existing preclinical and clinical data suggest that GLP\u20131 is involved in the AUD process and imply the role of GLP1\u2013RAs as a tentative treatment for AUD.<\/jats:p>","DOI":"10.3390\/ijms27104502","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:40:31Z","timestamp":1779115231000},"page":"4502","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Searching for New Pharmacological Treatments of Alcohol Use Disorder (AUD): Focus on GLP\u20131 Receptor Agonists"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3696-2389","authenticated-orcid":false,"given":"Jolanta B.","family":"Zawilska","sequence":"first","affiliation":[{"name":"Department of Pharmacodynamics, Medical University of Lodz, Muszy\u0144skiego 1, 90-151 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8713-2580","authenticated-orcid":false,"given":"Ewa","family":"Zwierzy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics, Medical University of Lodz, Muszy\u0144skiego 1, 90-151 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9903-7206","authenticated-orcid":false,"given":"Jakub","family":"Wojcieszak","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics, Medical University of Lodz, Muszy\u0144skiego 1, 90-151 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon\u2013like peptide 1 (GLP\u20131)","volume":"30","author":"Finan","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon\u2013like peptide\u20131 receptor: Mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/cne.24905","article-title":"A novel mouse model of glucagon\u2013like peptide\u20131 receptor expression: A look at the brain","volume":"528","author":"Graham","year":"2020","journal-title":"J. Comp. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.32598\/bcn.2021.2554.2","article-title":"Investigating the Glucagon\u2013like Peptide\u20131 and Its Receptor in Human Brain: Distribution of Expression, Functional Implications, Age\u2013related Changes and Species Specific Characteristics","volume":"14","author":"Gupta","year":"2023","journal-title":"Basic Clin. Neurosci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41387-025-00397-4","article-title":"Designing GLP\u20131 delivery: Structural perspectives and formulation approaches for optimized therapy","volume":"15","author":"Peri","year":"2025","journal-title":"Nutr. Diabetes"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Liu, Q.K. (2024). Mechanisms of action and therapeutic applications of GLP\u20131 and dual GIP\/GLP\u20131 receptor agonists. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1431292"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Chrysavgis, L., Mourelatou, N.G., and Cholongitas, E. (2025). Glucagon\u2013like Peptide\u20131 Receptor Agonists (GLP\u20131 RAs): A Pan\u2013Steatotic Liver Disease Treatment?. Biomedicines, 13.","DOI":"10.3390\/biomedicines13071516"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2024-335593","article-title":"Glucagon\u2013like peptide\u20131 receptor agonists for major neurocognitive disorders","volume":"96","author":"Ghenciulescu","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1017\/S1092852925000124","article-title":"The effect of glucagon\u2013like peptide\u20131 and glucose dependent insulinotropic polypeptide receptor agonists on neurogenesis, differentiation, and plasticity (Neuro\u2013GDP): Potential mechanistically informed therapeutics in the treatment and prevention of mental disorders","volume":"30","author":"McIntyre","year":"2025","journal-title":"CNS Spectr."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Moaket, O.S., Obaid, S.E., Obaid, F.E., Shakeeb, Y.A., Elsharief, S.M., Tania, A., Darwish, R., Butler, A.E., and Moin, A.S.M. (2025). GLP\u20131 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262110743"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s40200-025-01663-z","article-title":"The expanding role of semaglutide: Beyond glycemic control","volume":"24","author":"Zarei","year":"2025","journal-title":"J. Diabetes Metab. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon\u2013like peptide 1 (GLP\u20131) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_13","first-page":"1","article-title":"Alcohol use disorder: Pathophysiology, effects, and pharmacologic options for treatment","volume":"5","author":"Wackernah","year":"2014","journal-title":"Subst. Abus. Rehabil."},{"key":"ref_14","unstructured":"WHO (2026, February 10). Global Status Report on Alcohol and Health and Treatment of Substance Use Disorders. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240096745."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"112495","DOI":"10.1016\/j.drugalcdep.2024.112495","article-title":"The burden of alcohol and substance use disorders in adolescents and young adults","volume":"266","author":"Danpanichkul","year":"2025","journal-title":"Drug Alcohol Depend."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e172889","DOI":"10.1172\/JCI172889","article-title":"Novel medications for problematic alcohol use","volume":"134","author":"Heilig","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"107312","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review\u2014Glucagon\u2013like peptide\u20131 (GLP\u20131) and substance use disorders: An emerging pharmacotherapeutic target","volume":"207","author":"Bruns","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"bqaf028","DOI":"10.1210\/endocr\/bqaf028","article-title":"GLP\u20131 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder","volume":"166","author":"Jerlhag","year":"2025","journal-title":"Endocrinology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.psyneuen.2012.11.009","article-title":"The glucagon\u2013like peptide 1 analogue Exendin\u20134 attenuates alcohol mediated behaviors in rodents","volume":"38","author":"Egecioglu","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Shirazi, R.H., Dickson, S.L., and Skibicka, K.P. (2013). Gut peptide GLP\u20131 and its analogue, Exendin\u20134, decrease alcohol intake and reward. PLoS ONE, 28.","DOI":"10.1371\/journal.pone.0061965"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/acer.13199","article-title":"Effects of the GLP\u20131 Agonist Exendin\u20134 on Intravenous Ethanol Self\u2013Administration in Mice","volume":"40","author":"Caine","year":"2016","journal-title":"Alcohol Clin. Exp. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.pbb.2017.07.014","article-title":"The glucagon\u2013like peptide 1 receptor agonist Exendin\u20134 decreases relapse\u2013like drinking in socially housed mice","volume":"160","author":"Thomsen","year":"2017","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"ENEURO.0443-18.2019","DOI":"10.1523\/ENEURO.0443-18.2019","article-title":"Glucagon\u2013Like Peptide\u20131 Receptor Agonist Treatment Does Not Reduce Abuse\u2013Related Effects of Opioid Drugs","volume":"6","author":"Bornebusch","year":"2019","journal-title":"eNeuro"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00213-023-06367-x","article-title":"Sex\u2013dependent divergence in the effects of GLP\u20131 agonist exendin\u20134 on alcohol reinforcement and reinstatement in C57BL\/6J mice","volume":"240","author":"Thomsen","year":"2023","journal-title":"Psychopharmacology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/adb.12295","article-title":"The glucagon\u2013like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents","volume":"21","author":"Maccioni","year":"2016","journal-title":"Addict. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Marty, V.N., Farokhnia, M., Munier, J.J., Mulpuri, Y., Leggio, L., and Spigelman, I. (2020). Long\u2013Acting Glucagon\u2013Like Peptide\u20131 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats. Front. Neurosci., 14.","DOI":"10.3389\/fnins.2020.599646"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41398-020-00923-1","article-title":"Long\u2013term treatment with a glucagon\u2013like peptide\u20131 receptor agonist reduces ethanol intake in male and female rats","volume":"10","author":"Kalafateli","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Aran\u00e4s, C., Blid Sk\u00f6ldheden, S., and Jerlhag, E. (2023). Antismoking agents do not contribute synergistically to semaglutide\u2019s ability to reduce alcohol intake in rats. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1180512"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e170671","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon\u2013like peptide\u20131 (GLP\u20131) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00213-018-5089-z","article-title":"Effects of glucagon\u2013like peptide 1 analogs on alcohol intake in alcohol\u2013preferring vervet monkeys","volume":"236","author":"Thomsen","year":"2019","journal-title":"Psychopharmacology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00213-024-06637-2","article-title":"Effect of the glucagon\u2013like peptide\u20131 (GLP\u20131) receptor agonist semaglutide on alcohol consumption in alcohol\u2013preferring male vervet monkeys","volume":"242","author":"Klausen","year":"2025","journal-title":"Psychopharmacology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s11064-023-04093-6","article-title":"Liraglutide Reduces Alcohol Consumption, Anxiety, Memory Impairment, and Synapse Loss in Alcohol Dependent Mice","volume":"49","author":"Liu","year":"2024","journal-title":"Neurochem. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"104642","DOI":"10.1016\/j.ebiom.2023.104642","article-title":"Semaglutide reduces alcohol intake and relapse\u2013like drinking in male and female rats","volume":"93","author":"Edvardsson","year":"2023","journal-title":"EBioMedicine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"114187","DOI":"10.1016\/j.bcp.2020.114187","article-title":"Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer\u2019s and Parkinson\u2019s disease therapeutics","volume":"180","author":"Salameh","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Colvin, K.J., Killen, H.S., Kanter, M.J., Halperin, M.C., Engel, L., and Currie, P.J. (2020). Brain Site\u2013Specific Inhibitory Effects of the GLP\u20131 Analogue Exendin\u20134 on Alcohol Intake and Operant Responding for Palatable Food. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249710"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/acer.14437","article-title":"Glucagon\u2013Like Peptide\u20131 Receptor Signaling in the Ventral Tegmental Area Reduces Alcohol Self\u2013Administration in Male Rats","volume":"44","author":"Dixon","year":"2020","journal-title":"Alcohol Clin. Exp. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuropharm.2019.02.020","article-title":"Glucagon\u2013like peptide\u20131 receptors within the nucleus of the solitary tract regulate alcohol\u2013mediated behaviors in rodents","volume":"149","author":"Vestlund","year":"2019","journal-title":"Neuropharmacology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1037\/pha0000620","article-title":"Glucagon\u2013like peptide\u20131 receptors in nucleus accumbens, ventral hippocampus, and lateral septum reduce alcohol reinforcement in mice","volume":"31","author":"Allingbjerg","year":"2023","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Skibicka, K.P. (2013). The central GLP\u20131: Implications for food and drug reward. Front. Neurosci., 7.","DOI":"10.3389\/fnins.2013.00181"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"110640","DOI":"10.1016\/j.neuropharm.2025.110640","article-title":"Effects of glucagon\u2013like peptide 1 receptor signaling in the dorsolateral septum on ethanol operant self\u2013administration and relapse behaviors","volume":"279","author":"Xiao","year":"2025","journal-title":"Neuropharmacology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.psyneuen.2019.02.006","article-title":"Brain region specific glucagon\u2013like peptide\u20131 receptors regulate alcohol\u2013induced behaviors in rodents","volume":"103","author":"Kalafateli","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"105684","DOI":"10.1016\/j.ebiom.2025.105684","article-title":"An inhibitory GLP\u20131 circuit in the lateral septum modulates reward processing and alcohol intake in rodents","volume":"115","author":"Edvardsson","year":"2025","journal-title":"EBioMedicine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"106119","DOI":"10.1016\/j.ebiom.2025.106119","article-title":"Tirzepatide reduces alcohol drinking and relapse\u2013like behaviours in rodents","volume":"124","author":"Edvardsson","year":"2026","journal-title":"EBioMedicine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e13211","DOI":"10.1111\/adb.13211","article-title":"The glucagon\u2013like peptide\u20131 system is modulated by acute and chronic alcohol exposure: Findings from human laboratory experiments and a post\u2013mortem brain study","volume":"27","author":"Farokhnia","year":"2022","journal-title":"Addict. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1038\/tp.2015.68","article-title":"The glucagon\u2013like peptide\u20131 receptor as a potential treatment target in alcohol use disorder: Evidence from human genetic association studies and a mouse model of alcohol dependence","volume":"5","author":"Suchankova","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e159863","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo\u2013controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once\u2013Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e170419","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"ref_49","first-page":"100671","article-title":"Glucagon\u2013like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials","volume":"23","author":"Patil","year":"2026","journal-title":"Gov. Addict. Behav. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(26)00305-3","article-title":"Once\u2013weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: A randomised, double\u2013blind, placebo\u2013controlled trial","volume":"407","author":"Klausen","year":"2026","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"King, A.C., Wellendorf, C., Atkinson, E.A., de Carvalho, M.E.A., Fridberg, D.J., and Pannain, S. (2025). GLP\u20131 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study. J. Addict. Med.","DOI":"10.1097\/ADM.0000000000001565"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"23m15068","DOI":"10.4088\/JCP.23m15068","article-title":"Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series","volume":"85","author":"Richards","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder","volume":"82","author":"Tiihonen","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP\u20131 receptor agonists and subsequent risk of alcohol\u2013related events. A nationwide register\u2013based cohort and self\u2013controlled case series study","volume":"131","author":"Rungby","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/dom.16152","article-title":"Glucagon\u2013like peptide\u20131 analogues reduce alcohol intake","volume":"27","author":"Almohaileb","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/apt.70596","article-title":"Real\u2013World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP\u20131 Receptor Agonists Versus FDA\u2013Approved AUD Medications","volume":"63","author":"Gougol","year":"2026","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose\u2013dependent insulinotropic polypeptide and\/or glucagon\u2013like peptide\u20131 receptor agonist prescriptions and substance\u2013related outcomes in patients with opioid and alcohol use disorders: A real\u2013world data analysis","volume":"120","author":"Qeadan","year":"2024","journal-title":"Addiction"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real\u2013world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e188314","DOI":"10.1172\/JCI188314","article-title":"Glucagon\u2013like peptide\u20131 receptor agonists, but not dipeptidyl peptidase\u20134 inhibitors, reduce alcohol intake","volume":"135","author":"Farokhnia","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Abegaz, T.M., Ahmed, M., Bhagavathula, A.S., and Frietzem, G. (2026). Association between GLP\u20131 receptor agonist use and substance use disorders among individuals with type 2 diabetes or obesity: A nested case\u2013control study in the All of Us research program. Front. Psychiatry, 17.","DOI":"10.3389\/fpsyt.2026.1766770"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"20998","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_62","first-page":"5","article-title":"Social Media as Pharmacovigilance: The Potential for Patient Reports to Inform Clinical Research on Glucagon\u2013Like Peptide 1 (GLP\u20131) Receptor Agonists for Substance Use Disorders","volume":"85","author":"Bremmer","year":"2024","journal-title":"J. Stud. Alcohol Drugs"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Arillotta, D., Floresta, G., Papanti Pelletier, G.D., Guirguis, A., Corkery, J.M., Martinotti, G., and Schifano, F. (2024). Exploring the Potential Impact of GLP\u20131 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed\u2013Methods Approach. Brain Sci., 14.","DOI":"10.3390\/brainsci14060617"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cld.2018.09.011","article-title":"Epidemiology of Alcohol Consumption and Societal Burden of Alcoholism and Alcoholic Liver Disease","volume":"23","author":"Axley","year":"2019","journal-title":"Clin. Liver Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2021.7683","article-title":"Diagnosis and Treatment of Alcohol\u2013Associated Liver Disease: A Review","volume":"326","author":"Singal","year":"2021","journal-title":"JAMA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11030-025-11195-6","article-title":"GLP\u20131R agonists: Recent advances, current gaps, and future challenges","volume":"30","author":"Saran","year":"2026","journal-title":"Mol. Divers."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"115613","DOI":"10.1016\/j.bcp.2023.115613","article-title":"Glucagon\u2013like peptide 1 receptor agonist, exendin\u20134, reduces alcohol\u2013associated fatty liver disease","volume":"213","author":"Mahalingam","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s44324-025-00077-y","article-title":"GLP\u20131 receptor agonism results in reduction in hepatic ethanol metabolism","volume":"3","author":"Zahrawi","year":"2025","journal-title":"npj Metab. Health Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e16132","DOI":"10.1111\/liv.16132","article-title":"Impact of GLP\u20131RA on the Risk of Adverse Liver Outcomes Among Patients With Alcohol\u2013Associated Liver Disease and Type 2 Diabetes","volume":"45","author":"Rashid","year":"2025","journal-title":"Liver Int."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/apt.70007","article-title":"Impact of GLP\u20131 Receptor Agonists on Alcohol\u2013Related Liver Disease Development and Progression in Alcohol Use Disorder","volume":"61","author":"Kuo","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.physbeh.2016.04.013","article-title":"Central & peripheral glucagon\u2013like peptide\u20131 receptor signaling differentially regulate addictive behaviors","volume":"161","author":"Sirohi","year":"2016","journal-title":"Physiol. Behav."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/add.70374","article-title":"Glucagon\u2013like peptide\u20131 receptor agonists in alcohol use disorder: Multi\u2013system effects, early clinical promise and uncertain long\u2013term use","volume":"121","year":"2026","journal-title":"Addiction"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/10\/4502\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:27:53Z","timestamp":1779251273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/10\/4502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":72,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ijms27104502"],"URL":"https:\/\/doi.org\/10.3390\/ijms27104502","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}